# Gain Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Gain Therapeutics, Inc.). ## Overview Gain Therapeutics, Inc. is a U.S.-based early-stage biotechnology company developing next-generation brain-penetrant allosteric small molecules through its Magellan™ computational platform. Its lead clinical candidate, GT-02287, is being advanced for Parkinson’s disease and other neurodegenerative disorders, while the company also pursues discovery, preclinical work, and partnering opportunities around its platform technology. ## Products & services • Magellan™ computational platform for allosteric drug discovery • GT-02287 clinical-stage candidate for Parkinson’s disease • Preclinical brain-penetrant small-molecule programs • Collaboration and licensing arrangements for platform access • Co-development opportunities with third-party partners - **Clinical-stage drug candidate** (0%) — Lead therapeutic program being advanced through clinical development for neurodegenerative disease. - **Preclinical discovery pipeline** (0%) — Earlier-stage small-molecule programs generated from the company’s discovery efforts. - **Computational discovery platform** (0%) — Magellan™ identifies novel allosteric binding sites and potential drug candidates. - **Partnering and licensing** (100%) — Collaborations and licensing arrangements that monetize platform technology and know-how. - Magellan™ platform for discovering novel allosteric sites - GT-02287 for Parkinson’s disease and neurodegenerative diseases - Brain-penetrant small-molecule drug candidates - Preclinical discovery programs across multiple targets - Platform licensing, collaboration, and co-development deals ## Customers The company’s direct counterparties are pharmaceutical and biotechnology partners that may license or co-develop programs built on the Magellan™ platform. Its eventual end customers, if products are approved, would be patients and healthcare providers in neurology and other high-unmet-need therapeutic areas. At this stage, the business is funded primarily through capital markets and potential collaboration income rather than product sales. - **Pharmaceutical and biotech partners** (primary) — Buy access to platform-enabled discovery, licensing, or co-development rights to accelerate pipeline creation. - **Clinical development stakeholders** (primary) — Regulators, investigators, and trial sites that support advancement of GT-02287 and future candidates. - **Future patients and prescribers** (emerging) — Would use approved therapies for Parkinson’s disease and other neurodegenerative conditions. - Pharma partners seeking allosteric discovery capabilities - Biotech collaborators for co-development of novel programs - Potential licensees of Magellan™-derived assets - Patients with Parkinson’s and other neurodegenerative diseases - Healthcare providers treating high-unmet-need CNS disorders ## Geography Gain Therapeutics is headquartered in the United States and operates as a U.S.-listed development-stage biotech. Its supply chain is international: the company states that materials for product candidates are currently manufactured in China, creating exposure to trade policy and cross-border sourcing risk. Commercial geography is still limited because it has no approved products or product sales. - Headquartered in the United States - Clinical and regulatory activities are centered on U.S. development - Materials for product candidates are currently manufactured in China - Potential future commercialization would likely be multi-region - No disclosed country revenue because the company has no product sales ## Strategy The company’s strategy is to advance GT-02287 and other Magellan™-derived programs through preclinical and clinical development while preserving liquidity. It also seeks collaboration, licensing, and strategic alliance opportunities to fund development and potentially reduce the capital burden of building a full commercial organization. Because it remains pre-revenue, financing discipline and partnering are central to execution. - **Advance clinical-stage lead program** (short-term) — Clinical progress is the main source of value creation and partnering leverage. - **Secure non-dilutive or strategic funding** (short-term) — The company has no product revenue and needs capital to fund development. - **Broaden platform applications** (medium-term) — A wider target set can increase the probability of partnering and future pipeline value. - Advance GT-02287 through clinical development - Expand the Magellan™ platform into new targets and indications - Pursue collaboration and licensing deals to monetize technology - Preserve liquidity while funding R&D and trials - Use external capital to bridge to value-inflecting milestones ## Risks Gain Therapeutics faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need for repeated financing before any product revenue is possible. It also has meaningful supply-chain and geopolitical exposure because key materials are currently manufactured in China, while tariffs or trade restrictions could raise costs and slow development. As a pre-commercial company, its valuation is highly sensitive to trial outcomes, partnering success, and access to capital. - **Clinical development failure** [critical] — Lead programs may not demonstrate sufficient safety or efficacy to advance. - **Financing shortfall** [critical] — The company expects continued losses and negative operating cash flow. - **Regulatory delay or non-approval** [high] — FDA, EMA, or other agencies can slow or block development and commercialization. - **China sourcing and tariff exposure** [high] — APIs and other materials are currently manufactured in China, increasing cost and supply risk. - No approved products means no product revenue in the foreseeable future - Clinical trials may fail or take longer than expected - FDA/EMA review delays can slow commercialization - Funding risk is high because operations consume cash and losses continue - China-based sourcing exposes the company to tariffs and trade disruption - Partnering risk: collaboration deals may not materialize on favorable terms ## Accounting As a pre-revenue biotech, the most important accounting judgments are around R&D expense classification, stock-based compensation, and accruals for clinical and corporate obligations. The company also highlights recognition of research grants and estimates tied to accrued expenses and pension liabilities, which can move reported losses and balance-sheet liabilities. Because it has no product sales, there is no meaningful revenue-recognition complexity yet, but future collaboration accounting could become important if partnering expands. - **Research and development expense accruals** — Can shift quarterly operating loss and liabilities - **Stock-based compensation** — Affects operating expenses and comparability across periods - **Research grant recognition** — Can reduce net loss or offset R&D expense - **Collaboration and licensing accounting** — Could materially affect revenue timing if deals are signed - R&D expense timing drives most of the income statement - Stock-based compensation affects both operating loss and cash burn optics - Accrued expenses depend on estimates for trials, vendors, and services - Research grant recognition can affect other income and reported results - Future collaboration/licensing deals may create revenue recognition judgments --- *Last updated: 2026-04-28T20:10:53.901078+00:00*